Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan for Treatment of COVID-19 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years or older~* Confirmed diagnosis of COVID-19 by PCR test~* Hospitalization for COVID-19~* Illness symptoms beginning 4 days or less prior to randomization~Exclusion Criteria:~* Admitted to ICU prior to randomization~* Illness symptoms beginning more than 4 days prior to randomization~* Pregnancy~* Breast feeding~* Major hypersensibility to angiotensin receptor blockers (ARBs)~* Systolic blood pressure \< 100mmHg~* Potassium greater than 5.5 mEq/L~* AST and/or ALT \> 3 times the upper limit of normal~* Serum creatinine higher than 3 mg/dL~* Current treatment with angiotensin converting enzyme inhibitor (ACEi) or ARB

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TELMISARTAN (Type: EXPERIMENTAL): Patients in this group will receive 80 mg Telmisartan twice daily plus standard care.
- CONTROL (Type: NO_INTERVENTION): Patients in this group will receive standard care.

Based on this trial design, predict the completion outcome and termination type (if applicable).